203 related articles for article (PubMed ID: 33212545)
1. Trends in the Diagnosis and Treatment of Patients with Medullary Thyroid Carcinoma in Korea.
Ahn HY; Chae JE; Moon H; Noh J; Park YJ; Kim SG
Endocrinol Metab (Seoul); 2020 Dec; 35(4):811-819. PubMed ID: 33212545
[TBL] [Abstract][Full Text] [Related]
2. Vandetanib for the Management of Advanced Medullary Thyroid Cancer: A Real-World Multicenter Experience.
Kim M; Yoon JH; Ahn J; Jeon MJ; Kim HK; Lim DJ; Kang HC; Kim IJ; Shong YK; Kim TY; Kim BH
Endocrinol Metab (Seoul); 2020 Sep; 35(3):587-594. PubMed ID: 32981301
[TBL] [Abstract][Full Text] [Related]
3. Vandetanib for the treatment of advanced medullary thyroid cancer outside a clinical trial: results from a French cohort.
Chougnet CN; Borget I; Leboulleux S; de la Fouchardiere C; Bonichon F; Criniere L; Niccoli P; Bardet S; Schneegans O; Zanetta S; Schvartz C; Drui D; Chauffert B; Rohmer V; Schlumberger M
Thyroid; 2015 Apr; 25(4):386-91. PubMed ID: 25627619
[TBL] [Abstract][Full Text] [Related]
4. Risk Factors Associated With Reoperation and Disease-Specific Mortality in Patients With Medullary Thyroid Carcinoma.
Kuo EJ; Sho S; Li N; Zanocco KA; Yeh MW; Livhits MJ
JAMA Surg; 2018 Jan; 153(1):52-59. PubMed ID: 28973144
[TBL] [Abstract][Full Text] [Related]
5. Real-World Efficacy and Safety of Cabozantinib and Vandetanib in Advanced Medullary Thyroid Cancer.
Koehler VF; Adam P; Frank-Raue K; Raue F; Berg E; Hoster E; Allelein S; Schott M; Kroiss M; Spitzweg C
Thyroid; 2021 Mar; 31(3):459-469. PubMed ID: 32781914
[No Abstract] [Full Text] [Related]
6. External Beam Radiotherapy for Medullary Thyroid Cancer Following Total or Near-Total Thyroidectomy.
Jin M; Megwalu UC; Noel JE
Otolaryngol Head Neck Surg; 2021 Jan; 164(1):97-103. PubMed ID: 32746731
[TBL] [Abstract][Full Text] [Related]
7. Management of thyroid cancer: United Kingdom National Multidisciplinary Guidelines.
Mitchell AL; Gandhi A; Scott-Coombes D; Perros P
J Laryngol Otol; 2016 May; 130(S2):S150-S160. PubMed ID: 27841128
[TBL] [Abstract][Full Text] [Related]
8. An Overview of Medullary Thyroid Cancer Cases Treated at Kuwait Cancer Control Center.
Shete J; AlSaleh K; Safwat R; Bedair A; ElSherify M; Hussein A; Nazeeh M; Mohanty A
Gulf J Oncolog; 2020 Sep; 1(34):39-47. PubMed ID: 33431361
[TBL] [Abstract][Full Text] [Related]
9. [Postoperative external beam radiotherapy for medullary thyroid carcinoma with high risk of locoregional relapse].
Compagnon F; Zerdoud S; Rives M; Laprie A; Sarini J; Grunenwald S; Chaltiel L; Graff P
Cancer Radiother; 2016 Jul; 20(5):362-9. PubMed ID: 27396902
[TBL] [Abstract][Full Text] [Related]
10. Clinico-pathologic and dynamic prognostic factors in sporadic and familial medullary thyroid carcinoma: an Israeli multi-center study.
Twito O; Grozinsky-Glasberg S; Levy S; Bachar G; Gross DJ; Benbassat C; Rozental A; Hirsch D
Eur J Endocrinol; 2019 Jul; 181(1):13-21. PubMed ID: 31048559
[TBL] [Abstract][Full Text] [Related]
11. Serum Calcitonin-Negative Medullary Thyroid Carcinoma: A Case Series of 19 Patients in a Single Center.
Kim SJ; Yun HJ; Shin SJ; Lee YS; Chang HS
Front Endocrinol (Lausanne); 2021; 12():747704. PubMed ID: 34803914
[TBL] [Abstract][Full Text] [Related]
12. Surgical strategy for the treatment of sporadic medullary thyroid carcinoma: our experience.
Lupone G; Antonino A; Rosato A; Zenone P; Iervolino EM; Grillo M; De Palma M
G Chir; 2012; 33(11-12):395-9. PubMed ID: 23140924
[TBL] [Abstract][Full Text] [Related]
13. Cabozantinib and vandetanib for unresectable locally advanced or metastatic medullary thyroid cancer: a systematic review and economic model.
Tappenden P; Carroll C; Hamilton J; Kaltenthaler E; Wong R; Wadsley J; Moss L; Balasubramanian S
Health Technol Assess; 2019 Feb; 23(8):1-144. PubMed ID: 30821231
[TBL] [Abstract][Full Text] [Related]
14. The dilemma of metastatic medullary thyroid carcinoma: when to start systemic treatment.
Siano M; Alfieri S; Granata R; Calareso G; Orlandi E; Bergamini C; Locati LD
Tumori; 2019 Dec; 105(6):NP28-NP31. PubMed ID: 30782103
[TBL] [Abstract][Full Text] [Related]
15. Trends in Pediatric Thyroid Cancer Incidence, Treatment, and Clinical Course in Korea During 2004-2016: A Nationwide Population-Based Study.
Lee YA; Yun HR; Lee J; Moon H; Shin CH; Kim SG; Park YJ
Thyroid; 2021 Jun; 31(6):902-911. PubMed ID: 33107409
[No Abstract] [Full Text] [Related]
16. Metastatic medullary thyroid carcinoma (MTC): disease course, treatment modalities and factors predisposing for drug resistance.
Saltiki K; Simeakis G; Karapanou O; Paschou SA; Alevizaki M
Endocrine; 2023 Jun; 80(3):570-579. PubMed ID: 36626081
[TBL] [Abstract][Full Text] [Related]
17. Structural Doubling Time Predicts Overall Survival in Patients with Medullary Thyroid Cancer in Patients with Rapidly Progressive Metastatic Medullary Thyroid Cancer Treated with Molecular Targeted Therapies.
Yeh T; Yeung M; Sherman EJ; Tuttle RM; Sabra MM
Thyroid; 2020 Aug; 30(8):1112-1119. PubMed ID: 32131709
[No Abstract] [Full Text] [Related]
18. Association of Socioeconomic Status and Race/Ethnicity With Treatment and Survival in Patients With Medullary Thyroid Cancer.
Roche AM; Fedewa SA; Chen AY
JAMA Otolaryngol Head Neck Surg; 2016 Aug; 142(8):763-71. PubMed ID: 27254481
[TBL] [Abstract][Full Text] [Related]
19. Medullary thyroid carcinoma: clinical characteristics, treatment, prognostic factors, and a comparison of staging systems.
Kebebew E; Ituarte PH; Siperstein AE; Duh QY; Clark OH
Cancer; 2000 Mar; 88(5):1139-48. PubMed ID: 10699905
[TBL] [Abstract][Full Text] [Related]
20. Systemic treatment and management approaches for medullary thyroid cancer.
Ernani V; Kumar M; Chen AY; Owonikoko TK
Cancer Treat Rev; 2016 Nov; 50():89-98. PubMed ID: 27664392
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
